<?xml version="1.0" encoding="UTF-8"?>
<html xmlns="http://www.w3.org/1999/xhtml">
 <head charset="UTF-8"/>
 <style> * { font-family : helvetica;} .font17 { font-size : 17; } .font25 { font-size : 25; } .font10 { font-size : 10; } .font11 { font-size : 11; } .font12 { font-size : 12; } .font13 { font-size : 13; } .font30 { font-size : 30; } .font14 { font-size : 14; } .font15 { font-size : 15; }</style>
 <body>
  <p>
   <span class="font30">the </span>
   <span class="font25">and </span>
   <span class="font17">CMV </span>
   <span class="font17">with </span>
   <span class="font15">that </span>
   <span class="font15">for </span>
   <span class="font14">letermovir </span>
   <span class="font13">DNA </span>
   <span class="font13">The </span>
   <span class="font13">was </span>
   <span class="font13">viral </span>
   <span class="font13">cytomegalovirus </span>
   <span class="font13">terminase </span>
   <span class="font12">human </span>
   <span class="font12">are </span>
   <span class="font12">pUL </span>
   <span class="font12">transplant </span>
   <span class="font12">{background </span>
   <span class="font12">its </span>
   <span class="font12">antiviral </span>
   <span class="font12">treatment </span>
   <span class="font12">clinical </span>
   <span class="font11">were </span>
   <span class="font11">margin </span>
   <span class="font11">other </span>
   <span class="font11">complex </span>
   <span class="font11">drug </span>
   <span class="font11">not </span>
   <span class="font11">{border-style </span>
   <span class="font11">against </span>
   <span class="font11">this </span>
   <span class="font11">px;} </span>
   <span class="font11">#ffffff;} </span>
   <span class="font11">disease </span>
   <span class="font11">Phase </span>
   <span class="font11">drugs </span>
   <span class="font11">novel </span>
   <span class="font11">infection </span>
   <span class="font11">resistance </span>
   <span class="font11">Letermovir </span>
   <span class="font11">activity </span>
   <span class="font11">compared </span>
   <span class="font11">use </span>
   <span class="font11">from </span>
   <span class="font11">have </span>
   <span class="font11">into </span>
   <span class="font11">studies </span>
   <span class="font11">there </span>
   <span class="font10">currently </span>
   <span class="font10">has </span>
   <span class="font10">solid </span>
   <span class="font10">Virol </span>
   <span class="font10">also </span>
   <span class="font10">but </span>
   <span class="font10">effects </span>
   <span class="font10">mechanism </span>
   <span class="font10">organ </span>
   <span class="font10">pUL, </span>
   <span class="font10">patients </span>
   <span class="font10">potential </span>
   <span class="font10">prophylaxis </span>
   <span class="font10">protein </span>
   <span class="font10">significant </span>
   <span class="font10">vitro </span>
   <span class="font10">CMV, </span>
   <span class="font10">HSCT </span>
   <span class="font10">active </span>
   <span class="font10">adverse </span>
   <span class="font10">after </span>
   <span class="font10">daily </span>
   <span class="font10">doses </span>
   <span class="font10">prevention </span>
   <span class="font10">process </span>
   <span class="font10">proteins </span>
   <span class="font10">recipients </span>
   <span class="font10">study </span>
   <span class="font10">Drug </span>
   <span class="font10">This </span>
   <span class="font10">action </span>
   <span class="font10">benzimidazole </span>
   <span class="font10">due </span>
   <span class="font10">highly </span>
   <span class="font10">letermovir, </span>
   <span class="font10">levels </span>
   <span class="font10">mutations </span>
   <span class="font10">placebo </span>
   <span class="font10">px; </span>
   <span class="font10">recipients. </span>
   <span class="font10">replication </span>
   <span class="font10">strains </span>
   <span class="font10">subunit </span>
   <span class="font10">such </span>
   <span class="font10">termination </span>
   <span class="font10">translocation </span>
   <span class="font10">trial </span>
   <span class="font10">two </span>
   <span class="font10">when </span>
   <span class="font10">which </span>
   <span class="font10">{font-family </span>
   <span class="font10">GCV </span>
   <span class="font10">GCV, </span>
   <span class="font10">Its </span>
   <span class="font10">approved </span>
   <span class="font10">common </span>
   <span class="font10">font-size </span>
   <span class="font10">gene </span>
   <span class="font10">high </span>
   <span class="font10">kidney </span>
   <span class="font10">multidrug-resistant </span>
   <span class="font10">only </span>
   <span class="font10">portal </span>
   <span class="font10">received </span>
   <span class="font10">serum </span>
   <span class="font10">specific </span>
   <span class="font10">than </span>
   <span class="font10">these </span>
   <span class="font10">three </span>
   <span class="font10">BDCRB </span>
   <span class="font10">CMV. </span>
   <span class="font10">Infect </span>
   <span class="font10">These </span>
   <span class="font10">Transplant </span>
   <span class="font10">appears </span>
   <span class="font10">associated </span>
   <span class="font10">been </span>
   <span class="font10">capsid </span>
   <span class="font10">cell </span>
   <span class="font10">compound </span>
   <span class="font10">developed </span>
   <span class="font10">different </span>
   <span class="font10">dose </span>
   <span class="font10">double; </span>
   <span class="font10">functional </span>
   <span class="font10">group </span>
   <span class="font10">herpesviruses </span>
   <span class="font10">interaction </span>
   <span class="font10">lower </span>
   <span class="font10">may </span>
   <span class="font10">nuclear </span>
   <span class="font10">reported </span>
   <span class="font10">results </span>
   <span class="font10">safety </span>
   <span class="font10">side </span>
   <span class="font10">stem </span>
   <span class="font10">structure </span>
   <span class="font10">trials </span>
   <span class="font10">unique </span>
   <span class="font10">(which </span>
   <span class="font10">Agents </span>
   <span class="font10">CDV, </span>
   <span class="font10">Dis </span>
   <span class="font10">However, </span>
   <span class="font10">UL, </span>
   <span class="font10">allogeneic </span>
   <span class="font10">anti-CMV </span>
   <span class="font10">any </span>
   <span class="font10">border-color </span>
   <span class="font10">border-width </span>
   <span class="font10">cleavage </span>
   <span class="font10">data </span>
   <span class="font10">day </span>
   <span class="font10">does </span>
   <span class="font10">drugs. </span>
   <span class="font10">during </span>
   <span class="font10">effect </span>
   <span class="font10">encoded </span>
   <span class="font10">exhibit </span>
   <span class="font10">further </span>
   <span class="font10">genome </span>
   <span class="font10">had </span>
   <span class="font10">healthy </span>
   <span class="font10">importin </span>
   <span class="font10">inhibitor </span>
   <span class="font10">inhibitors </span>
   <span class="font10">interacts </span>
   <span class="font10">load </span>
   <span class="font10">low </span>
   <span class="font10">most </span>
   <span class="font10">packaging </span>
   <span class="font10">part </span>
   <span class="font10">patient </span>
   <span class="font10">profile </span>
   <span class="font10">promising </span>
   <span class="font10">protein), </span>
   <span class="font10">site </span>
   <span class="font10">solid; </span>
   <span class="font10">synthesis. </span>
   <span class="font10">their </span>
   <span class="font10">through </span>
   <span class="font10">using </span>
   <span class="font10">versus </span>
   <span class="font10">who </span>
   <span class="font10">{font-style </span>
   <span class="font10">{font-weight </span>
   <span class="font10">BAY </span>
   <span class="font10">C-terminal </span>
   <span class="font10">Chemother </span>
   <span class="font10">Goldner </span>
   <span class="font10">Tmax </span>
   <span class="font10">among </span>
   <span class="font10">antivirals </span>
   <span class="font10">bold </span>
   <span class="font10">bone </span>
   <span class="font10">can </span>
   <span class="font10">complex. </span>
   <span class="font10">concentration </span>
   <span class="font10">courier; </span>
   <span class="font10">cross-resistance </span>
   <span class="font10">days </span>
   <span class="font10">development </span>
   <span class="font10">effective </span>
   <span class="font10">efficacy </span>
   <span class="font10">em; </span>
   <span class="font10">essential </span>
   <span class="font10">evaluated </span>
   <span class="font10">failure </span>
   <span class="font10">finding </span>
   <span class="font10">given </span>
   <span class="font10">groups </span>
   <span class="font10">hematopoietic </span>
   <span class="font10">immune </span>
   <span class="font10">inhibition </span>
   <span class="font10">inhibits </span>
   <span class="font10">interactions </span>
   <span class="font10">known </span>
   <span class="font10">letermovir. </span>
   <span class="font10">lung </span>
   <span class="font10">major </span>
   <span class="font10">management </span>
   <span class="font10">marrow </span>
   <span class="font10">maturation </span>
   <span class="font10">multiple </span>
   <span class="font10">nuclease </span>
   <span class="font10">often </span>
   <span class="font10">open </span>
   <span class="font10">potent </span>
   <span class="font10">presented </span>
   <span class="font10">pt;} </span>
   <span class="font10">rate </span>
   <span class="font10">resistant </span>
   <span class="font10">risk </span>
   <span class="font10">sequence </span>
   <span class="font10">showed </span>
   <span class="font10">small </span>
   <span class="font10">standard </span>
   <span class="font10">subunits </span>
   <span class="font10">suggesting </span>
   <span class="font10">unit-length </span>
   <span class="font10">used </span>
   <span class="font10">very </span>
   <span class="font10">vivo </span>
   <span class="font10">will </span>
   <span class="font10">would </span>
  </p>
 </body>
</html>
